E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Disorder of Upper Respiratory System Laryngostenosis Tracheal Stenosis |
|
E.1.1.1 | Medical condition in easily understood language |
Narrowing of the larynx (voicebox) and upper trachea (windpipe). |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Ear, nose and throat diseases [C09] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10062034 |
E.1.2 | Term | Laryngeal operation |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10050816 |
E.1.2 | Term | Tracheal stenosis |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10023862 |
E.1.2 | Term | Laryngeal stenosis |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
We aim to assess the safety of stem cell based tissue engineered partial voice box replacement implants for the treatment of severe narrowing of the voice box and/or upper windpipe in adults. |
|
E.2.2 | Secondary objectives of the trial |
We also aim to assess the potential efficacy of stem cell based tissue engineered partial voice box replacement implants for the treatment of severe narrowing of the voice box and/or upper trachea.
Our objectives are to assess whether this treatment is effective in terms of significantly improving functions of breathing, speaking and swallowing, improving quality of life for patients and reducing the burden on healthcare systems. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients aged >=18 years with sufficient numbers of Mesenchymal Stromal Cells (MSCs) in their 8-10ml human Bone Marrow (hBM) aspirate procured at screening for the production of adequate cell numbers for TEP-PaL. Patients with Myer-Cotton Grade 3 or 4* laryngotracheal stenosis or equivalent morbidity due to traumatic, inflammatory, iatrogenic, neoplastic (benign or low grade malignant) or idiopathic causes who have exhausted conventional therapies. (This will be determined by a fully constituted complex airway multidisciplinary team).
*The Myer-Cotton grading system for mature, firm, circumferential stenosis, confined to the subglottis describes the stenosis based on the per cent relative reduction in cross-sectional area of the subglottis. Four grades of stenosis: • grade 1 lesions have less than 50% obstruction • grade 2 lesions have 51% to 70% obstruction • grade 3 lesions have 71% to 99% obstruction • grade 4 lesions have no detectable lumen or complete stenosis |
|
E.4 | Principal exclusion criteria |
Pregnancy. Those unable to provide informed consent. Co-morbid severe chronic obstructive pulmonary disease (COPD) (according to NICE clinical guideline CG101. Patients with active / uncontrolled chronic inflammatory conditions such as granulomatosis with polyangitis (formerly known as Wegener’s granulomatosis) and sarcoidosis. Any current or previous cancer within 5 years (except non-melanoma skin cancer, adequately treated carcinoma in situ of the uterine cervix, laryngeal malignancy treated locally without local recurrence or metastases or low grade airway tumours such as chondrosarcoma which may be causing airway obstruction. Life expectancy less than 5 years unless such limitation is largely due to the airway stenosis to be treated herein (as assessed by consultant trial clinician or referring clinician). Concurrent enrolment in any other CTIMP. Patients positive for HIV 1, HIV 2, HCV, HBV, syphilis or HTLV.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety as defined by mortality and morbidity as measured by occurrence of adverse events / reactions |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Throughout the whole study lifetime at each study visit up to 24 months post stage 2 implantation procedure. |
|
E.5.2 | Secondary end point(s) |
Efficacy as determined by: 1. Absence of tracheostomy 2. Absence of non-absorbable stent 3. Improvement in mean airway diameter 4. Improvement in FEV1 5. Improvement in global quality of life (EQ-5D) 6. Improvement in voice analysis operavox (VAO) including maximum phonation time (MPT) 7. Improvement in self assessment of voice handicap (VHI-10) 8. Improvement in swallowing function (EAT-10) 9. Improvement in airway, dyspnoea, voice, swallowing index (ADVS index) 10. Improvement in the penetration-aspiration scale (PAS) as per Video Fluoroscopic Swallow (VFS) or Functional Endoscopic Evaluation of Swallowing(FEES). Economic evaluations.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Efficacy as determined by: 1. Absence of tracheostomy (6,12,24 months) 2. Absence of non-absorbable stent (6,12,24 months) 3. Mean airway diameter (6,12,24 months) 4. FEV1 (1,2,6,12,24 months) 5. Global quality of life (EQ-5D)(1,2,6,12,24 months) 6. Voice analysis operavox (VAO) including maximum phonation time (MPT)(1,2,6,12,24 months) 7. Self assessment of voice handicap (VHI-10)(1,2,6,12,24 months) 8. Swallowing function (EAT-10) (1,2,6,12,24 months) 9. Airway, dyspnoea, voice, swallowing index (ADVS index) (1,2,6,12,24 months) 10. PAS as per Video Fluoroscopic Swallow (VFS) or Functional Endoscopic Evaluation of Swallow(FEES)(1wk, and 1,2,6, 12,24 months). Economic evaluations |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Health Economic evaluation |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
Early phase trial of an ATIMP surgically implanted in participants with laryngotracheal stenosis |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |